Teladoc Health Announces Deal With Northwell Health
The company's services will be white labeled under the hospital system’s brand.
Teladoc Health ($TDOC) announced today that it struck a deal with Northwell Health to provide its Microsoft-compatiable telehealth technology to the large New York metro area healthcare system.
Teladoc has deals with other healthcare systems, but a company spokesperson said this is the first to involve Solo, its product that works with Microsoft Teams. Microsoft's teleconferencing software.
The deal, the terms of which were not disclosed, does not involve the services of clinicians that work for Teladoc. Instead, the company's telehealth technology will be “white labeled” under the Northwell Health brand and Northwell clinicians will use it to provide telehealth services to their patients.
Northwell Health, headquartered in New Hyde Park, New York, bills itself as New York State’s largest healthcare provider. The system comprises 22 hospitals, including North Shore University Hospital and Long Island Jewish Medical Center.
Teladoc’s stock was trading at $58.32 when the markets closed today, slightly down from its opening price of $59.79.
Teladoc announced in July 2021 that it had developed a product called Solo that works with Microsoft Teams, a software platform that supports teleconferencing like Zoom but also has direct messaging and scheduling functions.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
